Should I buy or sell Spero Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares. View SPRO analyst ratings or view top-rated stocks .

What is Spero Therapeutics' stock price target for 2024?

2 brokerages have issued twelve-month price objectives for Spero Therapeutics' stock. Their SPRO share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 345.9% from the stock's current price. View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts .

How have SPRO shares performed in 2024?

Spero Therapeutics' stock was trading at $1.47 at the start of the year. Since then, SPRO stock has increased by 6.8% and is now trading at $1.57. View the best growth stocks for 2024 here .

When is Spero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SPRO earnings forecast .

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings data on Wednesday, March, 13th. The company reported $0.96 EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $1.14. The business had revenue of $73.52 million for the quarter, compared to analyst estimates of $19.40 million. Spero Therapeutics had a net margin of 21.98% and a trailing twelve-month return on equity of 38.54%.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com . Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Editas Medicine (EDIT) , SCYNEXIS (SCYX) , Kadmon (KDMN) , Aldeyra Therapeutics (ALDX) , KushCo (KSHB) , Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN) .

When did Spero Therapeutics IPO?

Spero Therapeutics (SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SPRO

Spero Therapeutics (SPRO) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free SPRO Stock Alerts

$1.57

+0.04 (+2.61%)

(As of 08:55 AM ET)

Compare

Today's Range: $1.57
▼
$1.57
50-Day Range: $1.35
▼
$1.80
52-Week Range: $0.99
▼
$2.00

Volume: 1,542 shs
Average Volume: 298,821 shs
Market Capitalization: $84.58 million

P/E Ratio: 3.74
Dividend Yield: N/A
Price Target: $7.00

Get Spero Therapeutics alerts:

Spero Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 345.9% Upside
$7.00 Price Target
Short Interest: Healthy
1.21% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.80
Upright™ Environmental Score
News Sentiment: 1.24
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.94) to ($0.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.54 out of 5 stars

Medical Sector

89th out of 928 stocks

Pharmaceutical Preparations Industry

27th out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Spero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Spero Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.21% of the outstanding shares of Spero Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Spero Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Spero Therapeutics has recently increased by 6.50%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Spero Therapeutics does not currently pay a dividend.
Dividend Growth
Spero Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Spero Therapeutics has received a 74.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Spero Therapeutics is -0.80.

2.9

News and Social Media Coverage

News Sentiment
Spero Therapeutics has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Spero Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Spero Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.21% of the stock of Spero Therapeutics is held by insiders.
Percentage Held by Institutions
Only 25.60% of the stock of Spero Therapeutics is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Spero Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Spero Therapeutics is 3.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of Spero Therapeutics is 3.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 166.67.
Price to Book Value per Share Ratio
Spero Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Spero Therapeutics Stock (NASDAQ:SPRO)

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

SPRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SPRO Stock News Headlines

April 12, 2024 | americanbankingnews.com

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above 200-Day Moving Average of $1.40

March 18, 2024 | markets.businessinsider.com

Spero Therapeutics’ Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 17, 2024 | finance.yahoo.com

Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

March 15, 2024 | finance.yahoo.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript

March 15, 2024 | finance.yahoo.com

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

March 14, 2024 | finanznachrichten.de

Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

March 14, 2024 | finance.yahoo.com

Q4 2023 Spero Therapeutics Inc Earnings Call

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 14, 2024 | markets.businessinsider.com

TD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)

March 13, 2024 | benzinga.com

Recap: Spero Therapeutics Q4 Earnings

March 13, 2024 | msn.com

Spero Therapeutics GAAP EPS of $0.96 beats by $1.06, revenue of $73.5M beats by $54.87M

March 13, 2024 | globenewswire.com

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

March 12, 2024 | msn.com

Spero Therapeutics Q4 2023 Earnings Preview

March 6, 2024 | globenewswire.com

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

February 28, 2024 | finanznachrichten.de

Spero Therapeutics, Inc.: Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

February 28, 2024 | markets.businessinsider.com

Spero Announces FDA Clearance Of IND Application For SPR206

February 28, 2024 | finance.yahoo.com

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

February 28, 2024 | globenewswire.com

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

February 26, 2024 | finance.yahoo.com

Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

February 26, 2024 | globenewswire.com

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

February 17, 2024 | ca.finance.yahoo.com

SPRO Apr 2024 2.000 put

February 17, 2024 | ca.finance.yahoo.com

SPRO Apr 2024 1.000 call

February 10, 2024 | msn.com

Spero Therapeutics Announces Chief Legal Officer’s Resignation

February 9, 2024 | uk.investing.com

Spero Therapeutics Inc (SPRO)

February 6, 2024 | finance.yahoo.com

Spero Therapeutics Inc CEO Sath Shukla Sells 75,994 Shares

January 31, 2024 | finance.yahoo.com

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See More Headlines

Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SPRO
CUSIP: N/A
CIK: 1701108
Web: sperotherapeutics.com
Phone: (857) 242-1600
Fax: N/A
Employees: 46
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +357.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.42
Trailing P/E Ratio: 3.64
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $22.81 million
Net Margins: 21.98%
Pretax Margin: 24.48%
Return on Equity: 38.54%
Return on Assets: 21.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.53
Quick Ratio: 3.53

Sales & Book Value

Annual Sales: $96.74 million
Price / Sales: 0.85
Cash Flow: $0.48 per share
Price / Cash Flow: 3.18
Book Value: $2.02 per share
Price / Book: 0.76

Miscellaneous

Outstanding Shares: 53,869,000
Free Float: 51,601,000
Market Cap: $82.42 million
Optionable: Optionable
Beta: 0.55

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Ankit Mahadevia M.D. (Age 43)
MBA, Co-Founder & Chairman of the Board
Comp: $1.39M
Mr. Satyavrat Shukla C.F.A. (Age 51)
President, CEO & Director
Comp: $1.12M
Mr. Timothy Keutzer (Age 56)
Chief Operating Officer
Comp: $938.57k
Ms. Esther P. Rajavelu (Age 45)
CFO & Chief Business Officer
Ted Jenkins
VP & Head of Investor Relations
Mr. James P. Brady
Chief Human Resource Officer
Dr. Kamal Hamed M.B.A. (Age 62)
M.D., M.P.H., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SPRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares.
View SPRO analyst ratings or view top-rated stocks.
What is Spero Therapeutics' stock price target for 2024?: 2 brokerages have issued twelve-month price objectives for Spero Therapeutics' stock. Their SPRO share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 345.9% from the stock's current price.
View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts.
How have SPRO shares performed in 2024?: Spero Therapeutics' stock was trading at $1.47 at the start of the year. Since then, SPRO stock has increased by 6.8% and is now trading at $1.57.
View the best growth stocks for 2024 here.
When is Spero Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SPRO earnings forecast.
How were Spero Therapeutics' earnings last quarter?: Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings data on Wednesday, March, 13th. The company reported $0.96 EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $1.14. The business had revenue of $73.52 million for the quarter, compared to analyst estimates of $19.40 million. Spero Therapeutics had a net margin of 21.98% and a trailing twelve-month return on equity of 38.54%.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?: 27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Spero Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).
When did Spero Therapeutics IPO?: Spero Therapeutics (SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
How do I buy shares of Spero Therapeutics?: Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SPRO) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial